December 18, 2024

Darzalex May Delay Myeloma in High-Risk Patients

For the first time, we have a treatment option that can significantly delay or prevent the progression to active disease."

Reuters

December 18, 2024

Physicians With Kids Face Large Pay Gaps

Physician compensation remains a central concern in health care, influenced by educational debt, specialty-specific variations, and evolving employer policies.

Conexiant

December 16, 2024

FDA Approves Unloxcyt for Skin Cancer

FDA approves Unloxcyt, a new drug by Checkpoint Therapeutics, for the treatment of advanced and metastatic cutaneous squamous cell carcinoma, showing promising results in clinical studies.

Reuters

December 16, 2024

FDA 6-Month Drug Pipeline

A pipeline of novel drugs awaits FDA review through the first half of 2025.

Conexiant

December 13, 2024

Adjuvant Tamoxifen May Reduce Recurrence Risk for Patients With ‘Good-Risk’ DCIS Who Forgo Radiation

For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast-conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence in the ...

The ASCO Post

December 12, 2024

Melanoma Recurrence Signs with ATLAS Guide

Study published in the Journal of the American Academy of Dermatology explores key symptoms and detection strategies for melanoma recurrence, providing potential improvements for surveillance protocols.

Conexiant

December 11, 2024

Triple-Drug Combos Show High Response Rates

Cutting-edge triple-drug therapies for leukemia discussed at the American Society of Hematology meeting show promising results in achieving remission and managing residual disease.

Reuters

December 11, 2024

New MRI Tech Targets Ovarian Tumors

Researchers have developed a groundbreaking MRI-based imaging technique that could revolutionize ovarian cancer treatment by customizing therapies and providing rapid treatment feedback within 48 hours. Source: Oncogene

Reuters

December 11, 2024

Study Links cfDNA Sequencing to Cancer Detection

Nearly 50% of pregnant participants with abnormal cell-free DNA sequencing results were found to have undiagnosed cancers, highlighting the potential of prenatal cell-free DNA screening to detect occult cancers.

Conexiant